Navigation Links
Mayo Clinic Proceedings: Gabapentin opens window of communication
Date:6/16/2010

ROCHESTER, Minn. -- For patients with quadriplegia, mutism and lower cranial nerve paralysis (locked-in syndrome), their only means of interacting with others is through vertical gaze and upper eyelid movements, using eye-coded communication strategies.

In the June issue of Mayo Clinic Proceedings, researchers from Italy describe four patients with locked-in syndrome who also had dancing eye syndrome (opsoclonus-myoclonus syndrome). Because these patients' eyes spontaneously and continuously oscillated in a variety of directions beyond their control, they could no longer interact with family members, physicians or other people.

The lead author, Francesca Pistoia, M.D., University of L'Aquila, Italy, reports that a decision was made to treat these patients with daily continuous gabapentin therapy based on a previous successful experience. Gabapentin was started as a single 300 mg dose on the first day followed by 600 milligrams per day in divided doses on the second day. In two of the patients, this dosage reduced ocular symptoms, and communication and quality of life improved. For the other two patients, the dose was further increased, with the best response achieved with a daily 1,200 mg dose.

In all four patients, attempts to stop treatment resulted in recurrence of dancing eye symptoms six hours after the last dose. Thus, gabapentin use was promptly resumed. Researchers found none of the patients experienced adverse effects from the treatment.

In an accompanying editorial, Joseph Sirven, M.D., Mayo Clinic neurologist, discusses the off-label use of gabapentin, which was approved by the U.S. Food and Drug Administration in 1994 for use as an adjunctive medication to control partial seizures. Dr. Sirven writes, "Ironically, despite the fact that the drug was invented and synthesized for its use in seizure prevention, its smallest market today is epilepsy and seizures."

"The study by Pistoia and colleagues has a potential profound impact for treatment of patients with locked-in syndrome and opsoclonus-myoclonus syndrome," writes Dr. Sirven. "Because this neurologic condition is so rare, small observational studies serve as the main source of clinical evidence and could be the cornerstone for clinical practice with no other evidence."


'/>"/>

Contact: Rebecca Finseth
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. BRAF inhibitor shows promising preclinical activity against melanoma
2. Free Clinics Play Important Role for Uninsured in U.S.
3. Sunrise Services Wins the Gold in Medisoft Clinical Sales Contest
4. Sanford Health Announces Sanford Children's Clinic in Klamath Falls, OR
5. Sharron Davies opens new respiratory research clinic
6. European patient survey add weight to expert call for greater clinical consensus on BTCP
7. FDA approves first human neural stem cell clinical trial to treat brain tumors
8. Antibody therapy lengthens survival of metastatic melanoma patients in large clinical trial
9. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
10. Fox Chase clinical trial tests first of its kind antibody
11. Launching Five Clinics on Wheels This Year, Ronald McDonald House Charities Celebrates Ten Years of the Ronald McDonald Care Mobile Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges the ... how his administration could impact the employee benefits industry. James Slotnick, AVP, Government ... likely to make it through Congress. His discussion will focus on the current ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would ... results in a fraction of the time as traditional braces – Wilckodontics®. Dr. ... Specialists, now offers this revolutionary treatment with or without a referral. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the ... dispensaries and head shops –can’t help but be heartened by the industry’s current surge. ... odor aptly described as “skunk smell.” At last they can simply, safely and ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine ... telehealth bundles, which pairs medical devices with a pre-programmed tablet in a remarkably ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
Breaking Medicine Technology: